

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Comparative Study of Corticosteroid Injection in the Caudal Epidural Space Under Fluoroscopy Guidance With or Without Ozone Injection in Lumbo-Sacral Radiculopathy: A Single-Blind Clinical Trial

Protocol summary

Study aim

To compare the efficacy of fluoroscopic-guided caudal epidural steroid injections with and without ozone therapy in reducing pain and improving functional outcomes in patients with lumbosacral radiculopathy caused by lumbar disc protrusion

Design

A single-center, single-blind, parallel-group randomised controlled trial with 40 patients randomly assigned into two equal groups. The study will compare the efficacy of caudal epidural steroid injections with and without ozone therapy. Outcome assessment will be blinded to ensure unbiased results

Settings and conduct

A single-center, single-blind trial at Imam Khomeini Hospital, Tehran, Iran, using fluoroscopic guidance. Participants will be monitored for safety, with treatment allocation blinded to participants and outcome assessors

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Patients aged 18-70 years with lumbosacral radiculopathy due to disc protrusion (L4-L5 or L5-S1) and symptoms persisting >3 months. Exclusion Criteria: History of spinal surgeries, severe systemic diseases, uncontrolled diabetes, infections, pregnancy, or cauda equina syndrome

Intervention groups

Group A: Caudal epidural steroid injection (8 mg dexamethasone, 5 mL lidocaine 1%, 3 mL normal saline). Group B: Same steroid injection as Group A + 5 mL ozone gas (10 µg/cc). Procedure: All injections under fluoroscopic guidance to ensure accuracy. The study compares the efficacy of steroid injections with and without ozone therapy for lumbosacral radiculopathy

Main outcome variables

Pain Intensity: Measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). Functional Disability: Assessed with the Oswestry

Disability Index (ODI), scored as a percentage (higher scores = greater disability). Timing of Measurements: At baseline, one month, and six months post-treatment

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20241214064051N1**

Registration date: **2025-02-15, 1403/11/27**

Registration timing: **registered_while_recruiting**

Last update: **2025-02-15, 1403/11/27**

Update count: **0**

Registration date

2025-02-15, 1403/11/27

Registrant information

Name

Nima Amiresmaili

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 6646 9824

Email address

nima.amiresmaili@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2025-01-24, 1403/11/05

Expected recruitment end date

2025-02-23, 1403/12/05

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparative Study of Corticosteroid Injection in the Caudal Epidural Space Under Fluoroscopy Guidance With or Without Ozone Injection in Lumbo-Sacral Radiculopathy: A Single-Blind Clinical Trial

Public title

Comparative Study of Corticosteroid Injection in the Caudal Epidural Space Under Fluoroscopy Guidance With or Without Ozone Injection in Lumbo-Sacral Radiculopathy: A Single-Blind Clinical Trial

Purpose

Health service research

Inclusion/Exclusion criteria**Inclusion criteria:**

Age between 18 and 70 years Diagnosed with low back pain (LBP) with radicular symptoms lasting more than three months and unresponsive to medical therapy, rest, and physical therapy Magnetic resonance imaging (MRI) evidence of lumbar intervertebral disc protrusion at the L4-L5 or L5-S1 levels

Exclusion criteria:

History of spinal fractures, inflammatory diseases, malignancy, or facet joint syndrome. Previous spinal surgeries uncontrolled diabetes mellitus neuropathy spondylolisthesis extruded discs severe knee osteoarthritis (grade 4), scoliosis clinical or laboratory evidence of infection Coagulopathy symptoms of cauda equina syndrome symptoms of cauda equina syndrome neurological disorders severe systemic diseases, mental illnesses current anticoagulant therapy Pregnancy or breastfeeding

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Forty patients meeting the inclusion criteria will be randomly assigned into two groups of 20 patients each using a computer-generated randomization list. Group A will receive a caudal epidural steroid injection, while Group B will receive the same injection plus ozone therapy. The participants and the physician assessing outcomes will be blinded to the type of procedure, though the operator performing the injections will be aware of the treatment administered.

Blinding (investigator's opinion)

Single blinded

Blinding description

In our randomized controlled trial comparing fluoroscopic-guided caudal epidural steroid injections with or without ozone therapy, we implemented blinding in specific groups to minimize bias. Below is a detailed description of the blinding process and its application to various roles involved in the study. 1. Participants (Patients) – Blinded □ The patients were unaware of which treatment they received (steroid injection alone or steroid + ozone injection). Since the injections were performed under the same procedural conditions for both groups, no distinguishing factors indicated the treatment assignment. 2. Principal Investigator – Not Blinded □ The principal investigator was involved in study design and oversight but was not blinded to treatment allocation. Given the need for procedural oversight and protocol adherence, they had access to treatment assignment information. 3. Healthcare Providers (Care Providers/Interventionists) – Not Blinded □ The physician performing the injections was aware of the treatment allocation since they had to prepare and administer the correct mixture. Due to the nature of the intervention (i.e., the inclusion of ozone gas in one group), it was not possible to blind the care provider. 4. Data Collectors – Blinded □ All data collectors, including those responsible for recording patient-reported pain scores and functional disability assessments, were blinded to the treatment assignment. This ensured that subjective measures such as the Visual Analog Scale (VAS) and the Oswestry Disability Index (ODI) were not influenced by knowledge of group allocation. 5. Outcome Assessors – Blinded □ The physician assessing clinical outcomes (pain and disability scores) was blinded to the treatment groups. Outcome assessments were conducted at baseline, 1 month, and 6 months post-procedure without knowledge of whether the patient received steroids alone or steroids plus ozone. 6. Data Analysts – Blinded (Unclear, Needs Clarification) □ The data analyst responsible for statistical analyses may or may not have been blinded. If blinding was applied, the dataset would have been coded in a way that concealed treatment allocation. If unblinded, this may have introduced potential bias in the interpretation of results. 7. Data Safety and Monitoring Board (DSMB) – Not Applicable □ The study did not include an independent Data Safety and Monitoring Board (DSMB), as it was a relatively small-scale clinical trial without external oversight. 8. Manuscript Writers – Not Blinded □ The authors of the manuscript had access to full study data and treatment allocation, which allowed for an informed discussion of results and clinical implications. Summary of Blinding Implementation Group Blinding Status Rationale Participants (Patients) □ Blinded Ensured unbiased patient-reported outcomes (VAS, ODI). Principal Investigator □ Not Blinded Required for study design and oversight. Care Providers (Interventionists) □ Not Blinded Needed to prepare and administer treatment. Data Collectors □ Blinded Ensured unbiased data collection of patient responses. Outcome Assessors □ Blinded Prevented bias in evaluating clinical outcomes. Data Analysts □ Unclear Should ideally be blinded to prevent bias in analysis. DSMB □ Not

Applicable No external monitoring board was used. Manuscript Writers Not Blinded Required access to complete data for reporting. How Blinding Was Achieved Randomization: Patients were randomly assigned to two treatment groups using a computer-generated randomization list. Standardized Procedures: Both groups underwent identical procedural steps, making it difficult for patients to distinguish between treatments. Separate Roles: The care provider (interventionist) was separate from the outcome assessor, ensuring the assessment process remained unbiased. Blinded Data Collection: The individuals collecting VAS and ODI scores were unaware of treatment allocation. Potential Data Analysis Blinding: If implemented, treatment codes were masked until the final statistical analysis was completed.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

The Ethics Committee of Human Research at Imam Khomeini Hospital.

Street address

Imam Khomeini Hospital, Keshavarz Boulevard, Tehran, Iran

City

tehran

Province

Tehran

Postal code

1419733141

Approval date

2024-10-28, 1403/08/07

Ethics committee reference number

IR.TUMS.IKHC.REC.1403.315

Health conditions studied**1****Description of health condition studied**

Lumbosacral Radiculopathy due to Lumbar Intervertebral Disc Protrusion (L4-L5 or L5-S1). This study focuses on chronic low back pain (LBP) with radicular symptoms, aiming to improve pain management and functional outcomes for patients with this condition.

ICD-10 code

M51.1

ICD-10 code description

Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy

Primary outcomes**1****Description**

Pain Intensity Measurement Method: Visual Analog Scale (VAS) Scale Range: 0 (No Pain) to 10 (Worst Pain Imaginable) Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy. Measurement Time Points: Baseline, 1 month, and 6 months post-injection

Timepoint

Pain Intensity Measurement Method: Visual Analog Scale (VAS) Scale Range: 0 (No Pain) to 10 (Worst Pain Imaginable) Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy. Measurement Time Points: Before intervention (Baseline) 1 month post-injection 3 months post-injection 6 months post-injection The measurement time points are clearly specified. The measurement method and scale range are explicitly stated

Method of measurement

Pain Intensity Measurement Method: Visual Analogue Scale for Pain Measurement Tool: Visual Analogue Scale Ruler for Pain Scale Range: 0 (No Pain) to 10 (Worst Pain Imaginable) Objective: To assess the patient's pain intensity before and after the intervention to determine treatment efficacy. Measurement Time Points: Before the intervention (Baseline) One month after injection Three months after injection Six months after injection

2**Description**

Functional Disability

Timepoint

Before the intervention (Baseline) One month after injection Three months after injection Six months after injection

Method of measurement

Measurement Method: Oswestry Disability Index Measurement Tool: Oswestry Disability Index Questionnaire Unit of Measurement: Percentage of functional disability caused by low back pain Objective: To assess the effect of treatment on patients' functional ability and reduction of limitations caused by pain Measurement

Secondary outcomes**1****Description**

Quality of Life

Timepoint

Time Points: Before the intervention (Baseline) One month after injection Three months after injection Six months after injection

Method of measurement

Measurement Method: World Health Organization Quality of Life Questionnaire Measurement Tool: World Health Organization Quality of Life Questionnaire - Short Version

(26 Questions)Unit of Measurement: Quality of life score based on participants' responses

Intervention groups

1

Description

Intervention Group:Group B (Steroid + Ozone Group):This group will receive the same steroid injection as the control group, with the addition of ozone gas.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Additional Component:5 mL of ozone gas at a concentration of 10 µg/cc.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space.

Category

Treatment - Other

2

Description

Control group:Group A (Steroid Group):This group will serve as the control group in the study and will receive only the steroid injection.Injection Details:Steroid Composition:8 mg dexamethasone.5 mL of 1% lidocaine.3 mL of normal saline.Procedure:All injections will be performed under fluoroscopic guidance in a sterile environment to ensure precise catheter placement in the epidural space.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Khomeini Hospital, Tehran, Iran.

Full name of responsible person

Nima Amiresmaili

Street address

Imam Khomeini Hospital, Keshavarz Boulevard,
Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1419733141

Phone

+98 21 6119 2929

Fax

+98 21 6646 1179

Email

nima.amiresmaili@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Manouchehr Moradi Sabzevar

Street address

Tehran University of Medical Sciences, Qods Street,
Enghelab Square, Tehran, Iran.

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

+98 21 8898 9110

Fax

+98 21 8898 9120

Email

research@tums.ac.ir

Web page address

<https://research.tums.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Nima Amiresmaili

Position

Non-Faculty Specialist Physician

Latest degree

Specialist

Other areas of specialty/work

Anesthesiology

Street address

Imam Khomeini Hospital, Keshavarz Boulevard,
Tehran, Iran. Postal Code: 1419733141

City

Babol
Province
Mazandaran
Postal code
1419733141
Phone
+98 911 218 2557
Email
nima.amiresmaili@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Nima Amiresmaili
Position
Fellowship assistant
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Tehran, Enghelab Square, 16 Azar Street, Central Building of the University of Tehran.
City
Tehran
Province
Tehran
Postal code
1419733141
Phone
+98 21 6646 9824
Fax
Email
nima.amiresmaili@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person

Nima Amiresmaili
Position
Fellowship assistant
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Tehran, Enghelab Square, 16 Azar Street, Central Building of the University of Tehran.
City
Tehran
Province
Tehran
Postal code
1419733141
Phone
+98 21 6646 9824
Fax
Email
nima.amiresmaili@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available